BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 17, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BC-3781: Completed Phase II enrollment

Nabriva completed enrollment of 210 patients in a double-blind, U.S. Phase II trial to compare twice-daily 100 and 150 mg IV BC-3781 vs. IV vancomycin. ...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >